Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study

Publikation: Beitrag in einer FachzeitschriftArtikelForschungBegutachtung

Abstract

The processes of drug development require efficient strategies to produce the respective drug metabolites, which are often difficult to obtain. Biotransformations employing recombinant microorganisms as whole-cell biocatalysts have become an attractive alternative to the chemical syntheses of such metabolites. For the first time, the potential of four different microbial systems expressing the human cytochrome P450 2D6 (CYP2D6), which is one of the most important drug-metabolizing enzymes, were compared and evaluated for such applications. The microbial host Pichia pastoris was the most efficient at expressing CYP2D6. Without additional over-expression of chaperons, the achieved yield of CYP2D6 was the highest of microbial hosts reported so far. Therefore, the system described in this study outperformed the previously reported expression of the N-terminally modified enzyme. It was also shown that the activities of the whole-cell conversions of bufuralol in recombinant P. pastoris were significantly higher than the Escherichia coli catalyst, which expressed the same unmodified gene.

Originalspracheenglisch
Seiten (von - bis)1346-1358
Seitenumfang13
FachzeitschriftBiotechnology Journal
Jahrgang7
Ausgabenummer11
DOIs
PublikationsstatusVeröffentlicht - 2012

Fingerprint

Cytochrome P-450 CYP2D6
Enzymes
Pharmaceutical Preparations
Pichia
Biotransformation
Escherichia coli
Genes

Fields of Expertise

  • Human- & Biotechnology

Treatment code (Nähere Zuordnung)

  • Experimental

Dies zitieren

Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study. / Geier, Martina; Braun, Andreas; Emmerstorfer, Anita; Pichler, Harald; Glieder, Anton.

in: Biotechnology Journal, Jahrgang 7, Nr. 11, 2012, S. 1346-1358.

Publikation: Beitrag in einer FachzeitschriftArtikelForschungBegutachtung

@article{46d236c0ea2a4a609d4d2087b3b157bc,
title = "Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study",
abstract = "The processes of drug development require efficient strategies to produce the respective drug metabolites, which are often difficult to obtain. Biotransformations employing recombinant microorganisms as whole-cell biocatalysts have become an attractive alternative to the chemical syntheses of such metabolites. For the first time, the potential of four different microbial systems expressing the human cytochrome P450 2D6 (CYP2D6), which is one of the most important drug-metabolizing enzymes, were compared and evaluated for such applications. The microbial host Pichia pastoris was the most efficient at expressing CYP2D6. Without additional over-expression of chaperons, the achieved yield of CYP2D6 was the highest of microbial hosts reported so far. Therefore, the system described in this study outperformed the previously reported expression of the N-terminally modified enzyme. It was also shown that the activities of the whole-cell conversions of bufuralol in recombinant P. pastoris were significantly higher than the Escherichia coli catalyst, which expressed the same unmodified gene.",
author = "Martina Geier and Andreas Braun and Anita Emmerstorfer and Harald Pichler and Anton Glieder",
note = "Copyright {\circledC} 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",
year = "2012",
doi = "10.1002/biot.201200187",
language = "English",
volume = "7",
pages = "1346--1358",
journal = "Biotechnology Journal",
issn = "1860-6768",
publisher = "Wiley-VCH",
number = "11",

}

TY - JOUR

T1 - Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study

AU - Geier, Martina

AU - Braun, Andreas

AU - Emmerstorfer, Anita

AU - Pichler, Harald

AU - Glieder, Anton

N1 - Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PY - 2012

Y1 - 2012

N2 - The processes of drug development require efficient strategies to produce the respective drug metabolites, which are often difficult to obtain. Biotransformations employing recombinant microorganisms as whole-cell biocatalysts have become an attractive alternative to the chemical syntheses of such metabolites. For the first time, the potential of four different microbial systems expressing the human cytochrome P450 2D6 (CYP2D6), which is one of the most important drug-metabolizing enzymes, were compared and evaluated for such applications. The microbial host Pichia pastoris was the most efficient at expressing CYP2D6. Without additional over-expression of chaperons, the achieved yield of CYP2D6 was the highest of microbial hosts reported so far. Therefore, the system described in this study outperformed the previously reported expression of the N-terminally modified enzyme. It was also shown that the activities of the whole-cell conversions of bufuralol in recombinant P. pastoris were significantly higher than the Escherichia coli catalyst, which expressed the same unmodified gene.

AB - The processes of drug development require efficient strategies to produce the respective drug metabolites, which are often difficult to obtain. Biotransformations employing recombinant microorganisms as whole-cell biocatalysts have become an attractive alternative to the chemical syntheses of such metabolites. For the first time, the potential of four different microbial systems expressing the human cytochrome P450 2D6 (CYP2D6), which is one of the most important drug-metabolizing enzymes, were compared and evaluated for such applications. The microbial host Pichia pastoris was the most efficient at expressing CYP2D6. Without additional over-expression of chaperons, the achieved yield of CYP2D6 was the highest of microbial hosts reported so far. Therefore, the system described in this study outperformed the previously reported expression of the N-terminally modified enzyme. It was also shown that the activities of the whole-cell conversions of bufuralol in recombinant P. pastoris were significantly higher than the Escherichia coli catalyst, which expressed the same unmodified gene.

U2 - 10.1002/biot.201200187

DO - 10.1002/biot.201200187

M3 - Article

VL - 7

SP - 1346

EP - 1358

JO - Biotechnology Journal

JF - Biotechnology Journal

SN - 1860-6768

IS - 11

ER -